

Freedom of Information Act 2000 - Request Reference FoI/23/383

Cancer treatment using Nivolumab

Information Requested:

Wilmington Healthcare is seeking to understand the initiation of patient treatment with Nivolumab and some additional products in different types of cancer. We would greatly appreciate if you could answer the following questions:

Q1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?

- Ipilimumab (monotherapy)
- Nivolumab (monotherapy)
- Nivolumab AND Ipilimumab (combination)
- Pembrolizumab
- Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
- Other active systemic anti-cancer therapy

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of renal cell carcinoma?

- Nivolumab (monotherapy)
- Nivolumab + Ipilimumab
- Nivolumab + Cabozantinib
- Avelumab + Axitinib

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q3. In the past 3 months, how many patients have been initiated* on the following agents for the treatment of gastric, gastro-oesophageal junction or oesophageal cancer:

- Nivolumab monotherapy or in combination with Ipilimumab
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Response Details:

Cardiff and Vale University Health Board (the UHB) does not hold this information. Under Section 16 of the FOIA, which provides us with the duty to advise and assist, the UHB can inform you that Velindre NHS Trust may hold information relevant to your request and can be contacted via the following link:

FOI.VUNHST@wales.nhs.uk